Patent Application
20160263102
(a) Field of the Invention
The present invention is directed to a pharmaceutical composition of bupropion or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt thereof. The invention is further directed to the use of said composition for affecting weight loss, supressing appetite and/or treating obesity-related conditions in individuals. Additionally, the present invention provides a method of manufacture of said composition.
(b) Description of the Related Art
Obesity is a disorder characterized by the accumulation of excess fat in the body. Obesity has been recognized as one of the leading causes of disease and is emerging as a global problem. Increased instances of complications such as hypertension, non-insulin dependent diabetes mellitus, arteriosclerosis, dyslipidemia, certain forms of cancer, sleep apnea, and osteoarthritis have been related to increased instances of obesity in the general population.
In addition to those individuals who satisfy a strict definition of medical obesity, a significant portion of the adult population is overweight. These overweight individuals would also benefit from the availability of an effective weight-loss composition.
Various drugs are currently available for management of obesity or affecting weight loss including orlistat, lorcaserin, sibutramine, exenatide, pramlintide, amphetamine, and a combination of phentermine and topiramate.
U.S. Pat. No. 7,425,571 discloses a method of treating obesity by administering zonisamide in combination with bupropion.
U.S. Pat. Nos. 7,056,890 and 7,659,256 disclose a composition comprising phentermine and topiramate and its use for effecting weight loss.
Recently a fixed dose combination of bupropion and naltrexone has been approved in the United States for affecting weight loss, supressing appetite and/or treating obesity-related conditions. The product is marketed in the United States by Takeda Pharmaceuticals under the brand name Contrave®. The product is in the form of a sustained release tri-layer tablet containing individual layers of bupropion and naltrexone separated by a sugar-containing intermediate layer.
Bupropion is used as an antidepressant. It has also been used either alone or in combination with other drugs as a smoking cessation aid. Bupropion hydrochloride is stable by itself under normal storage conditions, but can degrade in the presence of certain conventional excipients used in commercial formulations.
Naltrexone is an opioid antagonist. It is a synthetic congener of oxymorphone with no opioid agonist properties.
The bupropion and naltrexone combination has effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). The exact neurochemical effects of the combination leading to weight loss, however, is not fully understood.
U.S. Pat. Nos. 7,375,111; 7,462,626; and 8,722,085 disclose use of the combination of bupropion and naltrexone for treatment of being overweight and obesity.
U.S. Pat. No. 8,815,889 discloses a method of treating insulin resistance by administering bupropion in combination with naltrexone.
U.S. Pat. Nos. 8,088,786 and 8,318,788 disclose a layered composition of bupropion and naltrexone in which the two drug layers are separated by an intermediate layer containing sugar and a method of affecting weight loss by administering said composition. Such composition requires complicated manufacturing processes, the commercial manufacturing of such composition in turn consumes significant amounts of time and are cost intensive.
There is still a need for improved pharmaceutical compositions comprising bupropion and naltrexone as well as an improved and relatively simple process for preparing such preparations.
The present invention provides the following aspects, subject-matters and preferred embodiments, which respectively, taken alone or in combination, further contribute to solving the object of the present invention.
As described in further detail below, advantageously the pharmaceutical composition comprises a monolithic core, does not comprise a separate layer of bupropion or a pharmaceutically acceptable salt thereof or a separate layer of naltrexone or a pharmaceutically acceptable salt thereof. The composition is prepared using a simple and economical manufacturing process that is also suitable for large scale production.
In one aspect, the present invention provides a pharmaceutical composition comprising a core which comprises: bupropion or a pharmaceutically acceptable salt thereof, naltrexone or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients in the form of a matrix. Neither of the drugs represents a separate layer. The matrix further may comprise one or more release rate controlling agents. In an embodiment, the release rate controlling agent is provided in the form of a coating over the core containing the drug matrix.
In a further aspect, bupropion or a pharmaceutically acceptable salt thereof and naltrexone or a pharmaceutically acceptable salt thereof are in direct contact with each other. In an embodiment, the two drugs are not physically separated.
In another aspect, the pharmaceutical composition of the invention comprises bupropion or pharmaceutically acceptable salt thereof in a dose of about 30 mg to about 500 mg, and naltrexone or pharmaceutically acceptable salt thereof in a dose of about 1 mg to about 50 mg.
In an embodiment, the pharmaceutical composition of the invention comprises bupropion or pharmaceutically acceptable salt thereof in a dose of about 30 mg to about 300 mg, and naltrexone or pharmaceutically acceptable salt thereof in a dose of about 5 mg to about 50 mg.
In another aspect, bupropion or pharmaceutically acceptable salt thereof and/or naltrexone or pharmaceutically acceptable salt thereof in the composition exhibit sustained release.
In another aspect, each of bupropion or pharmaceutically acceptable salt thereof and naltrexone or pharmaceutically acceptable salt exhibit sustained release.
In another aspect, the present invention provides a pharmaceutical composition comprising a core which comprises: bupropion or pharmaceutically acceptable salt thereof, naltrexone or pharmaceutically acceptable salt thereof, one or more release rate controlling agents and one or more pharmaceutically acceptable excipients in the form of a matrix. The bupropion or pharmaceutically acceptable salt thereof and naltrexone or pharmaceutically acceptable salt thereof exhibit sustained release. The bupropion or pharmaceutically acceptable salt thereof and naltrexone or pharmaceutically acceptable salt thereof are administered in a single oral dosage form that is in the form of a tablet, pill, or capsule.
The core of the composition is in the form of one or more granules, tablets, or minitablets.
In another aspect, release of the drugs from the pharmaceutical composition is achieved by using a suitable dissolution release rate controlling agent(s) of hydrophilic, lipophilic or inert character or a combination of several different rate controlling agents providing sustained release of the drugs.
In another aspect, the rate controlling agent in the composition is in an amount in the range of 10% to 60% w/w of the core.
In another aspect, the invention provides a method of manufacturing the pharmaceutical composition of bupropion and naltrexone or pharmaceutically acceptable salts thereof, which process comprises the steps of:
In another aspect, the present invention provides the pharmaceutical composition as substantially described herein for use in the treatment of being overweight or obesity.
In another aspect, the present invention provides a method of affecting weight loss, supressing appetite and/or treating obesity-related conditions in individuals. The method comprises orally administering the pharmaceutical composition as substantially described herein.
Still other aspects and advantages of the invention will be apparent from the following detailed description of the invention.
The invention provides for a pharmaceutical composition comprising bupropion, naltrexone or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients in a single core. The drugs in the core are constituted in the form of a matrix. No drug portion in the composition represents a layer or is in the form of a layer.
The inventors have found that the composition according to the present invention can be prepared by a simple manufacturing process as it does not involve complexity of forming individual layers of the two drugs or separating the two layers with an intermediate layer.
A dissolution profile for a drug comprises the known dissolution rate and particular dissolution characteristics of the drug. A predictable dissolution profile for a specific drug allows for more accurate treatment of a given symptom. Predictable dissolution profiles for different drugs within a monolithic composition such as a tablet allow for coordinated treatment of multiple symptoms with a single pharmaceutical formulation.
It was also observed that when the monolithic composition comprising a fixed dose combination of bupropion and naltrexone or pharmaceutically acceptable salts thereof is ingested by a patient, each individual drug dissolves as predicted by its individual dissolution profile.
A further advantage of the monolithic composition is that the dissolution of both drugs is not affected in case the composition is attached to the lining of the stomach and the dissolution for both drugs occurs in a predictable rate.
As mentioned above, having a monolithic composition is desirable for ease of administration of multiple pharmaceutical compositions within a composition or dosage form such as a tablet.
The term “bupropion” and “naltrexone” denotes any pharmaceutical acceptable salts of bupropion and naltrexone. Within the meaning of the present invention, the term “bupropion” preferably refers to the active pharmaceutical ingredient “bupropion hydrochloride”. Within the meaning of the present invention, the term “naltrexone” preferably refers to the active pharmaceutical ingredient “naltrexone hydrochloride”. Within the context of the present specification, both bupropion and naltrexone are sometimes commonly referred to as “drugs”.
The term “matrix” as used herein throughout the specification denotes that the drugs (bupropion and naltrexone or a pharmaceutical acceptable salt thereof) and optionally release rate controlling agents are dispersed within the core either homogeneously or heterogeneously. In the homogeneous matrix system the drugs and optionally release rate controlling agents are distributed uniformly over the entire core, while in the heterogeneous matrix system the drugs and optionally release rate controlling agents are non-uniformly distributed over the entire core.
The term “controlled-release” is used herein in its ordinary sense and thus includes pharmaceutical compositions combined or coated with ingredients (e.g., rate controlling agents) to alter their dissolution profile. A “sustained-release” formulation is a type of controlled-release formulation in which the ingredients have been added to a pharmaceutical composition such that the dissolution profile is extended over a longer period of time than that of an immediate release formulation comprising a similar pharmaceutical composition.
According to the invention, the pharmaceutical composition comprises a core which comprises: bupropion or a pharmaceutically acceptable salt thereof, naltrexone or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients in the form of a homogeneous or heterogeneous matrix. Neither of the drugs represents a separate layer.
The matrix further may comprise one or more release rate controlling agents. In an embodiment, the release rate controlling agent is provided in the form of a coating over the core containing the drug matrix.
The composition of the invention exhibits excellent storage stability when subjected to storage at 40° C. and 75% relative humidity for a period of 3 months. The dosage form retains at least 95% of the total potency of bupropion and naltrexone upon storage.
The matrix core in the dosage form of the invention comprises bupropion or a pharmaceutically acceptable salt thereof, naltrexone or a pharmaceutically acceptable salt thereof, at least one release rate controlling agent, and one or more pharmaceutically acceptable excipients. In an embodiment, the core of the composition is in the form of one or more granules, tablets, or minitablets.
Preferably, the bupropion or a pharmaceutically acceptable salt thereof and the naltrexone or a pharmaceutically acceptable salt thereof in the composition are in direct contact with each other and/or not physically separated.
The pharmaceutical composition of the invention comprises bupropion or pharmaceutically acceptable salt thereof in a dose of about 30 mg to about 500 mg and naltrexone or pharmaceutically acceptable salt thereof in a dose of about 1 mg to about 50 mg. Preferably, the composition comprises bupropion or pharmaceutically acceptable salt thereof in a dose of about 30 mg to about 300 mg and naltrexone or pharmaceutically acceptable salt thereof in a dose of about 5 mg to about 50 mg.
Both bupropion or pharmaceutically acceptable salt thereof and naltrexone or pharmaceutically acceptable salt thereof in the composition may exhibit sustained release. In an embodiment, bupropion or its pharmaceutically acceptable salt thereof exhibits sustained release or naltrexone or its pharmaceutically acceptable salt exhibits sustained release.
The composition of bupropion or pharmaceutically acceptable salt thereof and naltrexone or pharmaceutically acceptable salt thereof is provided and administered in a single oral dosage form. Suitable dosage forms include, but are not limited to, the form of a tablet, pill, or capsule. Preferably the dosage form is a tablet.
Sustained release of the drugs from the pharmaceutical composition is achieved by using a suitable dissolution release rate controlling agent of hydrophilic, lipophilic or inert character or a combination of several different release rate controlling agents providing controlled release of the drugs.
Suitable release rate controlling agents, by way of example and without limitation, may be selected from the group consisting of hydrophilic agents, lipophilic agents and inert agents. The hydrophilic agents are selected from the group of pharmaceutical excipients which generate a gel in contact with water, including cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose and the like; noncellulose polysaccharides such as galactomannanes, guar gum, carob gum, gum arabicum, alginates, pectins, and the like; polyvinylpyrrolidone; polyvinylacetate polymers and copolymers; and acrylic acid polymers and copolymers, polyethylene oxide and mixtures thereof. The lipophilic agents are selected from the group consisting of waxes such as white wax, bees wax, carnauba wax and the like; fatty acids and alcohols such as stearic acid, palmitic acid, lauric acid and the like, and cetyl alcohol, cetostearyl alcohol, stearyl alcohol and the like; fatty acids esters such as monostearates of propylene glycol and fatty acid esters of sucrose, sucrose distearate and the like; and glycerides such as mono-, di- or triglycerides, e.g., palmitin, stearin, behenic, laurin, myristin, hydrogenated vegetable, castor, cottonseed oils, glyceril behenate and the like; and mixtures thereof. The inert agents are selected from the group consisting of thermoplastic polymers, which are insoluble and indigestible in the gastrointestinal fluids, such as polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymers, polymethylmethacrylates, polyamides, silicones, ethyl cellulose, polystyrene, and mixtures thereof. The release rate controlling agent in the composition is preferably present in an amount in the range of 10% to 60% w/w of the core.
The pharmaceutical composition may comprise one or more pharmaceutically acceptable excipients selected from the group consisting of binding agents, fillers, filler-binders, disintegrants, lubricants, sweeteners, glidants, flavourings and colouring agents.
The pharmaceutical composition may be configured in various shapes and sizes for ease of administration to a patient. Manufacture of pharmaceutical compositions configured in tablets comprises steps known in the art. For example, tablets may be prepared through wet-granulation, dry-granulation or direct compression.
In an embodiment, the method of manufacturing the pharmaceutical composition comprises the steps of:
The invention further provides the pharmaceutical composition of as substantially described herein for use in the treatment of overweight or obesity.
In invention further provides a method of affecting weight loss, supressing appetite and/or treating obesity-related conditions in individuals comprising administering the pharmaceutical composition as substantially described herein.
Bupropion HCl, Naltrexone HCl, Hydroxyethyl Cellulose, Hydroxypropyl Cellulose, Hydroxypropyl methylcellulose K100, Lactose Monohydrate and Magnesium Stearate were screened and blended together. The mixture was passed through a roller compactor and milled. The milled compacts were then blended with Colloidal Silicone Dioxide and Magnesium Stearate. Finally, the final blend was compressed into tablets using a rotary tablet press.
Naltrexone HCl, Bupropion HCl, Hydroxypropyl methylcellulose K 100, Carbomer Homopolymer (Type A) 971P, Carbomer Homopolymer (Type A) 71G, Lactose Monohydrate and Magnesium Stearate were screened and blended together. The mixture was passed through a roller compactor, and the resulting compacts were then milled. The milled compacts were blended with Colloidal Silicone Dioxide and Magnesium Stearate and the blend was compressed into tablets using a rotary tablet press. Separately, hydroxypropyl methylcellulose E5 was dissolved in purified water and mixed with ethyl cellulose aqueous dispersion under mixing. The tablets were coated with the dispersion using a perforated coating pan.
